Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.61 |
| ▸ | ENPP3 | O14638 | 3/20 | 0.55 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10114310 | 1.00 | NPY5R (0.61) | NPY5RENPP3ENPP1ENPP2TRPV1 | |
| SCHEMBL10114396 | 0.91 | NPY5R (0.60) | NPY5RENPP3ENPP1ENPP2NAMPT | |
| SCHEMBL10134426 | 0.91 | NPY5R (0.60) | NPY5RENPP3ENPP1ENPP2NAMPT | |
| SCHEMBL10113370 | 0.90 | NPY5R (0.72) | NPY5RENPP3ENPP1ENPP2TRPV1 | |
| SCHEMBL13203872 | 0.90 | NPY5R (0.72) | NPY5RENPP3ENPP1ENPP2TRPV1 | |
| SCHEMBL14424621 | 0.88 | LMNA (0.60) | NPY5RENPP3ENPP1ENPP2NAMPT | |
| SCHEMBL10134439 | 0.88 | NPY5R (0.57) | NPY5RENPP3ENPP1NAMPTGAA | |
| SCHEMBL10114303 | 0.88 | NPY5R (0.57) | NPY5RENPP3ENPP1ENPP2NAMPT | |
| SCHEMBL10113101 | 0.88 | NAMPT (0.66) | NPY5RNAMPTGAALMNAGLA | |
| SCHEMBL10114575 | 0.88 | LMNA (0.60) | NPY5RENPP3ENPP1ENPP2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015762-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | NPY5R 1/4885ENPP3 3334/4885ENPP1 3255/4885 |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | NPY5R 1/4885ENPP3 3225/4885ENPP1 3059/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | NPY5R 1/4885ENPP3 3416/4885ENPP1 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.